Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €12.14 EUR
Change Today +0.068 / 0.56%
Volume 0.0
RAH On Other Exchanges
As of 3:20 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

recro pharma inc (RAH) Key Developments

Recro Pharma, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 09:30 AM

Recro Pharma, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 09:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Geraldine A. Henwood, Chief Executive Officer, President and Director.

Recro Pharma, Inc. Reports Financial Results for the First Quarter Ended March 31, 2015

Recro Pharma, Inc. reported financial results for the first quarter ended March 31, 2015. For the first quarter of 2015, he c reported a net loss applicable to common shareholders of $4.1 million, or $0.53 per basic and diluted share, compared to a net loss applicable to common shareholders of $6.4 million, or $3.67 per basic and diluted share, for the comparable period in 2014.

Recro Pharma, Inc. Announces Update on On-Going Phase II Clinical Trial of Dex-In for Treatment of Acute Pain on Day 1 Following Surgery

Recro Pharma, Inc. announced that it had completed the prespecified interim analysis conducted on the company's Phase II, double-blind REC-14-013 trial of Dex-IN in patients who initiate dosing of study medication on Post Op Day 1 following bunionectomy surgery. The purpose of the interim analysis was to allow for a sample size adjustment, if necessary, to maintain the ability to detect a difference in treatment effects between Dex-IN and placebo. The trial was expected to enroll approximately 200-250 patients. As a result of the interim analysis, the total enrollment for the trial was adjusted to approximately 170 patients. The Phase II trial is a randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of Recro Pharma's proprietary intranasal formulation of dexmedetomidine, Dex-IN, in adult patients undergoing bunionectomy surgery, initiating dosing of study medication on Post Op Day 1. Patients who meet the eligibility criteria are randomized to either a 50µg dose of Dex-IN or a placebo intranasal dose given every 6 hours. Following the beginning of treatment, patients remain under observation for 48 hours at study centers. Patients are followed for 7 days after the initial dose of study medication. There is an oral opioid rescue treatment available to patients in either treatment group, if required, to provide adequate pain relief. The primary efficacy endpoint of the trial is the summed pain intensity difference over 48 hours, SPID48, starting on Post Op Day 1. Additional efficacy endpoints include use of opioid rescue medication, other pain parameters and opioid related side effects, as well as Patient Global Assessment (PGA) of pain control. Bunionectomy surgery generally involves an incision in the top or side of the big toe joint and the removal or realignment of soft tissue and bone. This is done to relieve pain and restore normal alignment to the joint. Bunionectomy surgery typically results in intense post-operative pain. In the past, drugs that have demonstrated analgesic effectiveness following bunionectomy surgery have frequently translated that analgesic success into other post-operative procedures that result in moderate to severe, acute pain.

Recro Pharma, Inc. Reports Earnings Results for the Fourth Quarter of 2014

Recro Pharma, Inc. reported earnings results for the fourth quarter of 2014. For the period, the company reported a net loss applicable to common shareholders of $3.5 million, or $0.45 per share, compared with a net loss for fourth quarter of 2013 of $496,927, or $3.19 per share. The per-share comparison was skewed by a surge in the number of shares outstanding to 7.7 million from just 155,600. The wider loss came as the company's quarterly research-and-development expenses surged to $2.3 million from $61,896 in the prior-year period. It isn't yet generating revenue.

Alkermes plc, Recro Pharma, Inc. - M&A Call

Recro Pharma to acquire IV/IM Meloxicam and Gainesville, GA GMP Manufacturing facility and business unit from Alkermes


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RAH:GR €12.14 EUR +0.068

RAH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RAH.
View Industry Companies

Industry Analysis


Industry Average

Valuation RAH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 6.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RECRO PHARMA INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at